App-Quantinova.ai

Risk Factors of Venous Thromboembolism in Patients with Varicose Disease of the Lower Extremities

O. Atamanyuk - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

N/A

Risk of bleeding and venous thromboembolism in patients using therapeutic dosage of Direct Oral Anticoagulants undergoing total hip or total knee arthroplasty

M. Smeets - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

N/A

Risk of long-term mortality in elderly patients with venous thrombosis

H. Wang - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

N/A

Rivaroxaban for the treatment of thrombosis in pediatric patients with leukemia. Results of a pilot study

S. Rodriguez Miranda - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

rivaroxaban

Rivaroxaban in patients with intestinal failure on parenteral nutrition (TINCRBEL study)

T. van Haaps - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

rivaroxaban

Rivaroxaban or placebo for extended antithrombotic prophylaxis after laparoscopic surgery for colorectal cancer

C. Becattini - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

rivaroxaban

Rotational thromboelastometry in heparin monitoring in critical COVID-19 disease.

L. Schulting - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

Heparin

Safe Timely resumption of Pharmacologic thromboembolism prevention in Hospitalized patients with A Recent Major Bleed

H. Sharma - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

N/A

Safety and Efficacy of Apixaban as Thromboprophylaxis in Multiple Myeloma Patients Receiving Chemotherapy: a Prospective Cohort Study

Z. Sayar - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

apixaban

Safety and efficacy of direct oral anticoagulant in elderly patients with cancer: real-world challenges

F. Haque - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

rivaroxaban

Safety and Efficacy of Emicizumab in People with Hemophilia A Enrolled in the Hemophilia Natural History Study (ATHN 7)

T. Buckner - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

FVIII

Safety and efficacy of splenectomy for the treatment of chronic immune thrombocytopenia (ITP).

A. Saldanha - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Venous thrombosis

N/A

SARS-CoV-2 Spike Protein Enhanced Thrombosis is inhibited by Tipiracil in Mice

W. Li - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

N/A

Secondary prevention of cardiogenic arterial thromboembolism in a patient with atrial fibrillation and thrombus in left ventricule

T. Saralidze - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

rivaroxaban

Serial D-dimers after anticoagulant cessation in unprovoked venous thromboembolism: data from the REVERSE cohort study

Y. Xu - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

Fibrinogen (IV)

Shortened Prothrombin Time and activated Partial Thromboplastin Time Tests as a Risk Factor for Venous or Arterial Thrombosis in Mexico

Y. Lee-Tsai - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

N/A

Small-molecule cyclophilin inhibitors as a potential therapeutic application to limit thrombosis

J. Van Bael - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

cyclosporin A

Splanchnic vein thrombosis and Budd-Chiari syndrome after SARS-CoV-2 vaccination – incidence of VITT

M. Lauw - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Venous thrombosis

N/A

Standard dosing of Enoxaparin Versus unfractionated heparin in critically ill COVID19 patients: A Multicenter Cohort Study

A. Hafiz - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

Heparin

Subtype-specific plasma signatures of platelet-related protein releasate in acute pulmonary embolism

G. Baidildinova - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

releasate

Filters

7277 Abstracts